We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01768403
First Posted: January 15, 2013
Last Update Posted: January 15, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Condition
Hypercholesterolemia Cardiovascular Disease Hypertension Diabetes Coronary Heart Disease Peripheral Arterial Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines. [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines. [ Time Frame: 24 weeks ]
    In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients

  • Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines [ Time Frame: 24 weeks ]
    Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven

  • Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines. [ Time Frame: 24 weeks ]
    For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class

  • The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models [ Time Frame: 24 weeks ]

Biospecimen Retention:   Samples Without DNA
Whole blood serum

Enrollment: 1236
Study Start Date: September 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Detailed Description:
Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  • Subject must be 19 years of age or older of either gender or race.
  • Subject must provide informed consent and comply with the survey procedures.
  • Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks
Criteria

Inclusion Criteria:

  • Subject must provide informed consent and comply with the survey procedures.
  • Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

- Subjects who are unwilling or unable to provide informed consent.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01768403


Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Habib BENNACEUR, MD AstraZeneca
Study Director: Nawel BOUTEKDJIRET, MD AstraZeneca
Principal Investigator: Yassin BOUHOUITA-GUERMECH, Professor Cardiology department /Mustapha Bacha Hospital
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01768403     History of Changes
Other Study ID Numbers: NIS-CDZ-XXX-2012/1
First Submitted: January 14, 2013
First Posted: January 15, 2013
Last Update Posted: January 15, 2013
Last Verified: January 2013

Keywords provided by AstraZeneca:
Hypercholesterolemia
Cardiovascular disease
Hypertension
Coronary Heart disease
Peripheral Arterial disease

Additional relevant MeSH terms:
Hypercholesterolemia
Hypertension
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Atherosclerosis